Physician profile
Greg Eric Halliday
NPI 1366431918
$3,312.22
in general payments reported to CMS, 2019-2025
26 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $887 · 2022: $522 · 2023: $803 · 2024: $673 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $764.19 | 2021-2025 | |
| Pfizer INC. | $542.51 | 2021-2025 | |
| Amgen INC. | $502.61 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $269.34 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.98 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $232.52 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $191.96 | 2021 | |
| Merck Sharp & Dohme LLC | $68.39 | 2021-2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $66.61 | 2021-2023 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $39.21 | 2021-2023 | Farxiga |
| Alnylam Pharmaceuticals INC. | $39.16 | 2022-2025 | Amvuttra |
| Heartflow, INC. | $35.15 | 2023 | Ffrct |
| Kowa Pharmaceuticals America, INC. | $33.75 | 2023-2024 | Livalo, Seglentis |
| Boston Scientific Corporation | $29.07 | 2021 | |
| Inspire Medical Systems, INC. | $28.01 | 2024 | Inspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $26.04 | 2024 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $25.69 | 2025 | Praluent, Evkeeza |
| Abbott Laboratories | $24.66 | 2021 | |
| Abiomed | $19.97 | 2024 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $18.27 | 2023 | Arcalyst |
| Altathera Pharmaceuticals LLC | $16.92 | 2021 | |
| Irhythm Technologies, INC. | $15.93 | 2022 | |
| Amarin Pharma, INC. | $15.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.69 | 2024 | |
| Organon LLC | $14.06 | 2021 | |
| Medtronic, INC. | $13.22 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Halliday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.